CellSeed
7776
Def Consulting
4833
Leoclan
7681
Timee
215A
Bank of Innovation
4393
JP Stock MarketDetailed Quotes
4553 TOWA Pharmaceutical
- 2800
- +10+0.36%
20min DelayNot Open Mar 25 15:30 JST
144.24BMarket Cap8.52P/E (Static)
2812High2771Low71.70KVolume2790Open2790Pre Close200.31MTurnover339552wk High0.31%Turnover Ratio51.52MShares248852wk Low391.66EPS TTM64.64BFloat Cap3560Historical High8.52P/E (Static)23.09MShs Float623Historical Low328.59EPS LYR1.47%Amplitude60.00Dividend TTM0.82P/B100Lot Size2.14%Div YieldTTM
TOWA Pharmaceutical News
TOWA Pharmaceutical: Notice regarding revisions to dividend forecasts for the fiscal year ending March 31, 2025 (69th term)
TOWA Pharmaceutical: Supplementary explanation of financial results for the 3rd quarter of the fiscal year ending March 31, 2025
TOWA Pharmaceutical: Summary of Financial Results for the 3rd Quarter of the Fiscal Year Ending March 31, 2025 [Japanese GAAP] (Consolidated)
TOWA Pharmaceutical: Confirmation letter
TOWA Pharmaceutical: Half-Year Report - 69th Term (2024/04/01 - 2025/03/31)
TOWA Pharmaceutical: Supplementary explanation of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3
TOWA Pharmaceutical: Summary of financial results for the 2nd quarter (interim period) of the fiscal year ending 2025/3 [Japanese GAAP] (consolidated)
TOWA Pharmaceutical: Notice regarding revisions to earnings forecasts
TOWA Pharmaceutical: Announcement of revised financial estimates.
TOWA Pharmaceutical: Supplementary explanation materials for Q1 financial results in March 2025.
TOWA Pharmaceutical: Short-term financial statements for the first quarter of March 2025 [Japanese standards] (consolidated)
TOWA Pharmaceutical: Confirmatory letter.
TOWA Pharmaceutical: Corrected Financial Report - 68th Term (2023/04/01 - 2024/03/31)
TOWA Pharmaceutical: Extraordinary Report
TOWA Pharmaceutical: Securities Report - 68th Period (April 1, 2023 - March 31, 2024)
TOWA Pharmaceutical: Confirmation letter
TOWA Pharmaceutical: Announcements of individual stocks regarding the financial results of the parent company.
TOWA Pharmaceutical: Supplementary explanation of financial results for the fiscal year ending 2024/3
TOWA Pharmaceutical: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Towa Pharmaceutical: Confirmation